Arysta

AI-Driven Integrated Immune Reprogramming

AI-Driven Integrated Immune
Reprogramming in Oncology

Designed to overcome cancer immune resistance by activating macrophages, NK cells, and T-cells. Unlocking macrophage-mediated anti-tumor responses across both solid tumors and hematologic malignancies.

Assets:

  • 1 IBI389 – CLDN18.2 × CD3 T-cell engager
  • 2 IMM01 – IRPa fusing protein
  • 3 IMM0306 – N CD47 x CD20 mAB-Trap fusion protein